Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Rybrevant is most often covered alongside Carvykti, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Rybrevant, all published on July 20, 2026.
Last mentioned: Jul 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Rybrevant is most often covered alongside Carvykti, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Rybrevant, all published on July 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rybrevant. Shared-story counts are live from our verified record — not editorial picks.
J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Source: The Motley Fool · fool.com
Rybrevant is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
